0001193125-20-171925.txt : 20200618 0001193125-20-171925.hdr.sgml : 20200618 20200618083841 ACCESSION NUMBER: 0001193125-20-171925 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200617 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20200618 DATE AS OF CHANGE: 20200618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 20971302 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 8-K 1 d906808d8k.htm 8-K 8-K
false 0001157601 0001157601 2020-06-17 2020-06-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): J une 17, 2020 (June 17, 2020)

 

MADRIGAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

  

001-33277

  

04-3508648

(State or another jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

     

Four Tower Bridge

200 Barr Harbor Drive, Suite 200

West Conshohocken, Pennsylvania

  

19428

(Address of principal executive offices)

  

(Zip Code)

(267) 824-2827

Registrant’s telephone number, including area code

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 Par Value Per Share

  

MDGL

  

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) 2020 Annual Meeting of Stockholders

The Company held a virtual Annual Meeting, via Internet webcast, at 9:00 a.m., Eastern time, on Wednesday, June 17, 2020. As of April 24, 2020, the record date for the Annual Meeting, the Company had 15,429,154 shares of its common stock outstanding and entitled to vote, of which 14,339,286 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote, constituting a quorum, at the Annual Meeting.

(b) Annual Meeting Voting Results

The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting. These matters are described in more detail in the Proxy Statement.

Proposal No. 1: The Company’s stockholders elected each of the three Class I nominees named below to serve on the Company’s Board of Directors for a three-year term expiring at the Company’s 2023 annual meeting of stockholders and until their respective successors are duly elected and qualified.

Class I Nominee

 

Votes For

   

Votes Withheld

   

Broker Non-votes

 

Paul A. Friedman, M.D.

   

11,237,483

     

680,239

     

2,421,564

 

Kenneth M. Bate

   

10,223,285

     

1,694,464

     

2,421,564

 

James M. Daly

   

10,197,153

     

1,720,569

     

2,421,564

 

Proposal No. 2: The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

14,334,506

 

4,175

 

605

 

—  

Proposal No. 3: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement.

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

11,799,778

 

93,291

 

24,653

 

2,421,564

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MADRIGAL PHARMACEUTICALS, INC.

             

Date: June 18, 2020

 

 

 

/s/ Brian J. Lynch

 

 

 

Brian J. Lynch

 

 

 

Senior Vice President and General Counsel

EX-101.SCH 2 mdgl-20200617.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 mdgl-20200617_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 mdgl-20200617_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ZIP 5 0001193125-20-171925-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-171925-xbrl.zip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end XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Jun. 17, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001157601
Document Type 8-K
Document Period End Date Jun. 17, 2020
Entity Registrant Name MADRIGAL PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-33277
Entity Tax Identification Number 04-3508648
Entity Address, Address Line One Four Tower Bridge
Entity Address, Address Line Two 200 Barr Harbor Drive
Entity Address, Address Line Three Suite 200
Entity Address, City or Town West Conshohocken
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19428
City Area Code (267)
Local Phone Number 824-2827
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 Par Value Per Share
Trading Symbol MDGL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d906808d8k.htm mdgl-20200617.xsd mdgl-20200617_lab.xml mdgl-20200617_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d906808d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d906808d8k.htm" ] }, "labelLink": { "local": [ "mdgl-20200617_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mdgl-20200617_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mdgl-20200617.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mdgl", "nsuri": "http://www.madrigalpharma.com/20200617", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d906808d8k.htm", "contextRef": "duration_2020-06-17_to_2020-06-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d906808d8k.htm", "contextRef": "duration_2020-06-17_to_2020-06-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com//20200617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 11 d906808d8k_htm.xml IDEA: XBRL DOCUMENT 0001157601 2020-06-17 2020-06-17 false 0001157601 8-K 2020-06-17 MADRIGAL PHARMACEUTICALS, INC. DE 001-33277 04-3508648 Four Tower Bridge 200 Barr Harbor Drive Suite 200 West Conshohocken PA 19428 (267) 824-2827 false false false false Common Stock, $0.0001 Par Value Per Share MDGL NASDAQ false XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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